Is QNCX or ENTX more profitable?

Entera Bio's return on equity of -83.31% beat Quince Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A -372.88% -67.99% Entera Bio N/A -83.31% -70.83%

Which has higher valuation & earnings, FLNA or QNCX?

Cassava Sciences is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$1.61 N/A Quince Therapeutics N/A N/A -$83.98M -$10.62 N/A

Is FLNA or QNCX more profitable?

Cassava Sciences' return on equity of -53.90% beat Quince Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -53.90% -34.20% Quince Therapeutics N/A -372.88% -67.99%

Do analysts prefer QNCX or EXOZ?

Quince Therapeutics presently has a consensus price target of $65.00, suggesting a potential upside of 6,907.33%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Quince Therapeutics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is QNCX or EXOZ more profitable?

eXoZymes' return on equity of -220.63% beat Quince Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A -372.88% -67.99% eXoZymes N/A -220.63% -141.26%

Is QNCX or IMA more profitable?

ImageneBio's return on equity of -38.96% beat Quince Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A -372.88% -67.99% ImageneBio N/A -38.96% -34.60%

Quince Therapeutics (QNCX) Competitors

$0.93 -0.02 (-1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$0.92 -0.01 (-1.14%)

As of 07:59 PM Eastern

Compare

QNCX vs. ENTX, MNOV, FLNA, EXOZ, and IMA

Should you buy Quince Therapeutics stock or one of its competitors? MarketBeat compares Quince Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quince Therapeutics include Entera Bio (ENTX), MediciNova (MNOV), Cassava Sciences (FLNA), eXoZymes (EXOZ), and ImageneBio (IMA). These companies are all part of the "pharmaceutical products" industry.

How does Quince Therapeutics compare to Entera Bio?

Quince Therapeutics (NASDAQ:QNCX) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

Entera Bio's return on equity of -83.31% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-67.99%
Entera Bio	N/A	-83.31%	-70.83%

Quince Therapeutics presently has a consensus target price of $65.00, indicating a potential upside of 6,907.33%. Entera Bio has a consensus target price of $9.00, indicating a potential upside of 508.11%. Given Quince Therapeutics' higher possible upside, equities analysts clearly believe Quince Therapeutics is more favorable than Entera Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Entera Bio had 5 more articles in the media than Quince Therapeutics. MarketBeat recorded 5 mentions for Entera Bio and 0 mentions for Quince Therapeutics. Entera Bio's average media sentiment score of 0.50 beat Quince Therapeutics' score of 0.00 indicating that Entera Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Quince Therapeutics	Neutral
Entera Bio	Neutral

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 7.1% of Quince Therapeutics shares are held by company insiders. Comparatively, 10.6% of Entera Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Quince Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Entera Bio has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

Entera Bio has higher revenue and earnings than Quince Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A
Entera Bio	$40K	1,823.73	-$11.44M	-$0.27	N/A

Summary

Entera Bio beats Quince Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Quince Therapeutics compare to MediciNova?

Quince Therapeutics (NASDAQ:QNCX) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 7.1% of Quince Therapeutics shares are owned by company insiders. Comparatively, 14.0% of MediciNova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Quince Therapeutics has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-67.99%
MediciNova	-1,962.98%	-27.28%	-25.24%

MediciNova has higher revenue and earnings than Quince Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A
MediciNova	$410K	156.06	-$12M	-$0.23	N/A

In the previous week, MediciNova had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 1 mentions for MediciNova and 0 mentions for Quince Therapeutics. MediciNova's average media sentiment score of 0.59 beat Quince Therapeutics' score of 0.00 indicating that MediciNova is being referred to more favorably in the news media.

Company	Overall Sentiment
Quince Therapeutics	Neutral
MediciNova	Positive

Quince Therapeutics presently has a consensus price target of $65.00, indicating a potential upside of 6,907.33%. MediciNova has a consensus price target of $8.33, indicating a potential upside of 541.03%. Given Quince Therapeutics' higher probable upside, research analysts plainly believe Quince Therapeutics is more favorable than MediciNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Quince Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Summary

MediciNova beats Quince Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Quince Therapeutics compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Cassava Sciences is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A

Cassava Sciences has a beta of -0.72, suggesting that its stock price is 172% less volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Cassava Sciences currently has a consensus target price of $5.00, indicating a potential upside of 303.23%. Quince Therapeutics has a consensus target price of $65.00, indicating a potential upside of 6,907.33%. Given Quince Therapeutics' higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Cassava Sciences' return on equity of -53.90% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Quince Therapeutics	N/A	-372.88%	-67.99%

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 7.1% of Quince Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Cassava Sciences' average media sentiment score of 0.00 equaled Quince Therapeutics'average media sentiment score.

Company	Overall Sentiment
Cassava Sciences	Neutral
Quince Therapeutics	Neutral

Summary

Cassava Sciences beats Quince Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Quince Therapeutics compare to eXoZymes?

Quince Therapeutics (NASDAQ:QNCX) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Quince Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.66, meaning that its share price is 166% more volatile than the broader market.

In the previous week, eXoZymes had 2 more articles in the media than Quince Therapeutics. MarketBeat recorded 2 mentions for eXoZymes and 0 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.00 equaled eXoZymes'average media sentiment score.

Company	Overall Sentiment
Quince Therapeutics	Neutral
eXoZymes	Neutral

30.8% of Quince Therapeutics shares are held by institutional investors. 7.1% of Quince Therapeutics shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Quince Therapeutics presently has a consensus price target of $65.00, suggesting a potential upside of 6,907.33%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Quince Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

eXoZymes has higher revenue and earnings than Quince Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A
eXoZymes	$70K	990.95	-$9.16M	-$1.14	N/A

eXoZymes' return on equity of -220.63% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-67.99%
eXoZymes	N/A	-220.63%	-141.26%

Summary

eXoZymes beats Quince Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Quince Therapeutics compare to ImageneBio?

Quince Therapeutics (NASDAQ:QNCX) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Quince Therapeutics currently has a consensus target price of $65.00, suggesting a potential upside of 6,907.33%. ImageneBio has a consensus target price of $26.50, suggesting a potential upside of 342.40%. Given Quince Therapeutics' higher probable upside, analysts plainly believe Quince Therapeutics is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Quince Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

In the previous week, ImageneBio had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 1 mentions for ImageneBio and 0 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.00 equaled ImageneBio'saverage media sentiment score.

Company	Overall Sentiment
Quince Therapeutics	Neutral
ImageneBio	Neutral

ImageneBio has higher revenue and earnings than Quince Therapeutics. ImageneBio is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A
ImageneBio	$800K	79.74	-$45.35M	-$5.79	N/A

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 75.0% of ImageneBio shares are held by institutional investors. 7.1% of Quince Therapeutics shares are held by company insiders. Comparatively, 2.2% of ImageneBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ImageneBio's return on equity of -38.96% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-67.99%
ImageneBio	N/A	-38.96%	-34.60%

Summary

ImageneBio beats Quince Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Quince Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNCX vs. The Competition

Export

Metric	Quince Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.41M	$3.41B	$6.43B	$12.54B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-0.09	19.52	24.98	24.33
Price / Sales	N/A	330.92	529.24	114.72
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	-0.14	8.34	10.85	6.58
Net Income	-$83.98M	$23.80M	$3.56B	$336.75M
7 Day Performance	-0.37%	3.63%	0.70%	-0.49%
1 Month Performance	-15.67%	1.77%	0.29%	1.56%
1 Year Performance	-92.86%	58.60%	30.68%	33.78%

Quince Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNCX Quince Therapeutics	1.3189 of 5 stars	$0.93 -1.9%	$65.00 +6,907.3%	-92.7%	$15.41M	N/A	N/A	60	Gap Down
ENTX Entera Bio	2.4098 of 5 stars	$1.21 -1.6%	$9.00 +643.8%	-38.9%	$60.63M	$40K	N/A	20	News Coverage Gap Up Trading Halted
MNOV MediciNova	1.9862 of 5 stars	$1.25 +1.6%	$8.33 +566.7%	+2.3%	$60.54M	$410K	N/A	10	News Coverage Gap Up High Trading Volume
FLNA Cassava Sciences	1.5029 of 5 stars	$1.21 -3.2%	$5.00 +313.2%	-38.7%	$60.38M	N/A	N/A	20
EXOZ eXoZymes	0.2244 of 5 stars	$7.35 +3.5%	N/A	-14.4%	$60.20M	$70K	N/A	29

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNCX) was last updated on 6/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quince Therapeutics (QNCX) Competitors

QNCX vs. ENTX, MNOV, FLNA, EXOZ, and IMA

How does Quince Therapeutics compare to Entera Bio?

Summary

How does Quince Therapeutics compare to MediciNova?

Summary

How does Quince Therapeutics compare to Cassava Sciences?

Summary

How does Quince Therapeutics compare to eXoZymes?

Summary

How does Quince Therapeutics compare to ImageneBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quince Therapeutics (QNCX) Competitors

QNCX vs. ENTX, MNOV, FLNA, EXOZ, and IMA

How does Quince Therapeutics compare to Entera Bio?

Is QNCX or ENTX more profitable?

Do analysts recommend QNCX or ENTX?

Does the media prefer QNCX or ENTX?

Do institutionals & insiders hold more shares of QNCX or ENTX?

Which has more volatility and risk, QNCX or ENTX?

Which has higher valuation & earnings, QNCX or ENTX?

Summary

How does Quince Therapeutics compare to MediciNova?

Do insiders & institutionals believe in QNCX or MNOV?

Is QNCX or MNOV more profitable?

Which has stronger earnings & valuation, QNCX or MNOV?

Does the media favor QNCX or MNOV?

Do analysts rate QNCX or MNOV?

Which has more risk and volatility, QNCX or MNOV?

Summary

How does Quince Therapeutics compare to Cassava Sciences?

Which has higher valuation & earnings, FLNA or QNCX?

Which has more volatility and risk, FLNA or QNCX?

Do analysts rate FLNA or QNCX?

Is FLNA or QNCX more profitable?

Do insiders and institutionals believe in FLNA or QNCX?

Does the media refer more to FLNA or QNCX?

Summary

How does Quince Therapeutics compare to eXoZymes?

Which has more risk and volatility, QNCX or EXOZ?

Does the media favor QNCX or EXOZ?

Do institutionals & insiders have more ownership in QNCX or EXOZ?

Do analysts prefer QNCX or EXOZ?

Which has better earnings and valuation, QNCX or EXOZ?

Is QNCX or EXOZ more profitable?

Summary

How does Quince Therapeutics compare to ImageneBio?

Do analysts prefer QNCX or IMA?

Which has more volatility and risk, QNCX or IMA?

Does the media favor QNCX or IMA?

Which has higher valuation and earnings, QNCX or IMA?

Do insiders & institutionals have more ownership in QNCX or IMA?

Is QNCX or IMA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools